Provista Diagnostics is celebrating some early clinical data that support its approach of using autoantibodies and serum protein biomarkers together to help differentiate between invasive breast cancer and benign breast conditions.
In a preclinical study, San Francisco-based Nektar Therapeutics found that its investigational cancer drug, NKTR-214, inhibited growth in highly aggressive tumors, showing potential to treat a variety of cancers.
Results are in from a showdown between chronic lymphocytic leukemia drugs Imbruvica, from Johnson & Johnson's Janssen unit, and GlaxoSmithKline's Arzerra. And as it turns out, it wasn't much of a contest.
Now that the Pfizer takeover AstraZeneca fought to avoid is on the rocks--at least for the time being--the pressure's on the British drugmaker to deliver strong growth on its own. And while much of the attention is focused on its pipeline, leading cancer drug Zoladex may be able to chip in, too, with new data suggesting it could help prevent infertility in some breast cancer patients receiving chemo.
On Thursday, John Carroll and Dr. David Porter, one of the top investigators on the CAR-T team at the University of Pennsylvania, discussed how this program promises to be a game changer in cancer treatment in the first of a three-part Twitter chat around this year's ASCO conference. Here is a wrapup of the conversation.
Glaxo announced at ASCO on Sunday that in a Phase III study, Tykerb and Herceptin failed to improve disease-free survival in HER2-positive early breast cancer patients over Herceptin on its own.
Eli Lilly wrestled its way into the spotlight at ASCO Saturday morning with evidence that its cancer drug ramucirumab delivers a marginal benefit for patients suffering from advanced non-small cell lung cancer. And analysts quickly heralded the data, saying it should help pave the way to quickly broaden the market for this drug.
AbbVie's experimental leukemia drug ABT-199 is continuing to wow analysts with some stellar early-stage data. At the interim point of a Phase Ib study, ABT-199/GDC-0199 combined with rituximab registered an 84% overall response rate among patients with chronic lymphocytic leukemia.
Clovis Oncology has come out of the gate at ASCO with updated--and promising--data on its targeted lung cancer drug CO-1686, offering fresh evidence of its durability and effectiveness.
Today, Roche put out the word that their PD-L1 drug MPDL3280A won the FDA's coveted breakthrough therapy designation, potentially putting it on an inside track at the agency, which has been hurrying along new medicines in the pipeline.